Literature DB >> 9685235

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.

J M Klunder1, M Hoermann, C L Cywin, E David, J R Brickwood, R Schwartz, K J Barringer, D Pauletti, C K Shih, D A Erickson, C L Sorge, D P Joseph, S E Hattox, J Adams, P M Grob.   

Abstract

Like other nonnucleoside inhibitors of HIV-1 reverse transcriptase, the dipyridodiazepinone nevirapine (Viramune, 1) selects for drug resistant variants of HIV-1, both in cell culture and in patients. In particular, the mutation of residue 181 from tyrosine to cysteine (Y181C) is associated with resistance to most reported nonnucleoside inhibitors. Introduction of an arylethyl substituent at the 8-position of the tricyclic dipyridodiazepinone skeleton confers enhanced potency against Y181C RT. Several analogues of this series display good broad spectrum potency against a panel of mutant enzymes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685235     DOI: 10.1021/jm9707028

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Dipyridodiazepinone derivatives; synthesis and anti HIV-1 activity.

Authors:  Nisachon Khunnawutmanotham; Nitirat Chimnoi; Arunee Thitithanyanont; Patchreenart Saparpakorn; Kiattawee Choowongkomon; Pornpan Pungpo; Supa Hannongbua; Supanna Techasakul
Journal:  Beilstein J Org Chem       Date:  2009-07-22       Impact factor: 2.883

Review 2.  Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Valeria Famiglini; Romano Silvestri
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.